Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amcad BiomedROCO:4188 -0.32%53 Median PS Value is NT$9.67 as of Aug. 02, 2026, which is 100% below its 10-year median of 1.52. GuruFocus rates ROCO:4188 with a GF Score™ of 53/100 and a GF Value™ of NT$9.10 (Fairly Valued). The stock has 4 warning signs investors should review. Among 335 Medical Devices & Instruments companies, Amcad Biomed ranks worse than 77.61% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Amcad Biomed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.481. Amcad Biomed's 10-Year median PS Ratio is 20.104. Therefore, the Median PS Value for today is NT$9.67.
As of today (2026-08-02), Amcad Biomed's share price is NT$9.45. Amcad Biomed's Median PS Value is NT$9.67. Therefore, Amcad Biomed's Price to Median PS Value for today is 0.98.
The historical rank and industry rank for Amcad Biomed's Median PS Value or its related term are showing as below:
ROCO:4188'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.98 Med: 1.52 Max: 1.52
Current: 0.98
During the past 13 years, the highest Price to Median PS Value of Amcad Biomed was 1.52. The lowest was 0.98. And the median was 1.52.
ROCO:4188's Price-to-Median-PS-Value is ranked worse than 77.61% of 335
companies
in the Medical Devices & Instruments industry
Industry Median: 0.7
vs ROCO:4188: 0.98
Amcad Biomed (ROCO:4188) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Amcad Biomed's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
9.45
/
9.67
=
0.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amcad Biomed Median PS Value Related Terms
Amcad Biomed Median PS Value Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4188 vs ABT, SYK, MDT: Median PS Value Comparison
For the Medical Devices subindustry, Amcad Biomed's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 20.104.
Amcad Biomed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.481.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amcad Biomed (ROCO:4188) has a Median PS Value of NT$9.67 as of Aug. 02, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Amcad Biomed and its competitors. This is 536% above median its historical median of 1.52. Over the past decade, Amcad Biomed's Median PS Value has ranged from 0.98 to 1.52. According to the industry distribution chart, Amcad Biomed ranks #260 out of 335 companies in the Medical Devices & Instruments industry, placing it in the top 77.6%.
Is Amcad Biomed's Median PS Value too high?
Amcad Biomed's current Median PS Value of NT$9.67 is 536% above median its 10-year median of 1.52. Over the past 10 years, this metric has ranged from a low of 0.98 to a high of 1.52. Based on the distribution chart, Amcad Biomed ranks #260 out of 335 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Amcad Biomed has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Median PS Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #260 out of 335 companies for Median PS Value. This places Amcad Biomed in the lower half of its industry. The industry median Median PS Value is 0.70. Historically, Amcad Biomed's own Median PS Value has ranged from 0.98 to 1.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.70, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Amcad Biomed and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current Median PS Value is NT$9.67, which is 536% above median its own 10-year median of 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.10, compared to a current price of NT$9.45 — trading 3.8% above its estimated fair value. The current Median PS Value is NT$9.67, which is 536% above median its 10-year median of 1.52. Amcad Biomed's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Median PS Value is NT$9.67 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$9.45 is trading 3.8% above its estimated GF Value™ of NT$9.10.
GuruFocus considers Amcad Biomed to be Fairly Valued.
Key valuation signals for ROCO:4188:
Median PS Value: NT$9.67 (536% above median its 10-year median of 1.52)
GF Value™: NT$9.10 vs. price of NT$9.45 (3.8% above fair value)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
53GF Score
Get the complete analysis for ROCO:4188
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
